Overview

A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy

Status:
Completed
Trial end date:
2008-08-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the study drug is safe and effective in preventing hepatic encephalopathy (HE).
Phase:
Phase 3
Details
Lead Sponsor:
Bausch Health Americas, Inc.
Valeant Pharmaceuticals International, Inc.
Treatments:
Rifamycins
Rifaximin